Two other prevalent ADHD treatments referred to as methylphenidate and lisdexamfetamine dimesylate also remain in shortage, in accordance with the company's documents, since the FDA initially announced provide shortfalls in July previous year. Tiny trials have described comparable effectiveness to Vyvanse. 1 study noted that each appeared equally